



(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 5/0783 (2010.01)
A61N 1/00 (2006.01) C12N 13/00 (2006.01)

(21) International Application Number:

PCT/IB2024/053054

(22) International Filing Date:

28 March 2024 (28.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/493,141 30 March 2023 (30.03.2023) US
63/599,142 15 November 2023 (15.11.2023) US

(71) Applicant: NOVOCURE GMBH [CH/CH]; 6 Park, 6039
Root D4 (CH).

(72) Inventors: KAN, Tal; c/o Novocure GmbH, Topaz Building,
4th Floor, MATAM Center, P.O. Box 15022, Sha'ar
HaCarmel, 31905 Haifa (IL). BARSHESET, Yiftah; c/o
Novocure GmbH, Topaz Building, 4th Floor, MATAM Center,
P.O. Box 15022, Sha'ar HaCarmel, 31905 Haifa (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS
AND KILLER CELLS




FIG. 4

(57) Abstract: Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition comprising at least one killer cell (such as, but not limited to, at least one natural killer (NK) cell or at least one cytokine-induced killer (CIK) cell).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*